Evidence map›Paper›PMID 36142820›Full record

ArticleInternational journal of molecular sciences2022

COVID-19, Vaccination, and Female Fertility in the Czech Republic.

Lucie Kolatorova, Karolina Adamcova, Jana Vitku, Lenka Horackova, Marketa Simkova, Marketa Hornova, Michala Vosatkova, Veronika Vaisova, Antonin Parizek, Michaela Duskova

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Lucie KolatorovaDepartment of Steroids and Proteofactors, Institute of Endocrinology, Narodni 8, 116 94 Prague, Czech Republic.ORCID 0000-0002-8206-4598
Karolina AdamcovaDepartment of Obstetrics and Gynecology, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Apolinarska 18, 128 51 Prague, Czech Republic.
Jana VitkuDepartment of Steroids and Proteofactors, Institute of Endocrinology, Narodni 8, 116 94 Prague, Czech Republic.ORCID 0000-0003-0805-7602
Lenka HorackovaDepartment of Steroids and Proteofactors, Institute of Endocrinology, Narodni 8, 116 94 Prague, Czech Republic.
Marketa SimkovaDepartment of Steroids and Proteofactors, Institute of Endocrinology, Narodni 8, 116 94 Prague, Czech Republic.ORCID 0000-0002-0417-9867
Marketa HornovaDepartment of Obstetrics and Gynecology, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Apolinarska 18, 128 51 Prague, Czech Republic.
Michala VosatkovaDepartment of Clinical Biochemistry, Institute of Endocrinology, Narodni 8, 116 94 Prague, Czech Republic.
Veronika VaisovaDepartment of Obstetrics and Gynecology, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Apolinarska 18, 128 51 Prague, Czech Republic.
Antonin ParizekDepartment of Obstetrics and Gynecology, General University Hospital, 1st Faculty of Medicine, Charles University in Prague, Apolinarska 18, 128 51 Prague, Czech Republic.
Michaela DuskovaDepartment of Steroids and Proteofactors, Institute of Endocrinology, Narodni 8, 116 94 Prague, Czech Republic.

Funding

Ministry of Health Czech Republic MH CZ - DRO, Institute of Endocrinology EÚ, 00023761
6 · The paper itself

Abstract

The fast-track process to approve vaccines against COVID-19 has raised questions about their safety, especially in relation to fertility. Over the last 2 years, studies have appeared monitoring female fertility, especially from assisted reproduction centers or in animal experiments. However, studies monitoring healthy populations are still limited. The aim of our study was to monitor the relevant parameters of female fertility (sex and other steroids, LH, FSH, SHBG, Antimüllerian hormone and antral follicle count) before and then 2-4 months after the third dose of vaccination against COVID-19 in a group of 25 healthy fertile woman. In addition, anti-SARS-CoV-2 and anti-SARS-CoV-2S antibodies were determined. We did not observe significant changes in the measured parameters before and after the third dose of vaccination. By comparing levels of the analytes with antibodies indicating a prior COVID-19 infection, we found that women who had experienced the disease had statistically lower levels of estrone, estradiol, SHBG and 5α-dihydroprogesterone, and conversely, higher levels of androgen active dehydroepiandrosterone and dihydrotestosterone. Our results confirm that vaccination does not affect female fertility, and that what fertile women should be worried about is not vaccination, but rather COVID-19 infection itself.

Indexed as

Anti-Mullerian HormoneCOVID-1920-alpha-DihydroprogesteroneAndrogensAnimalsCOVID-19 VaccinesCzech RepublicDehydroepiandrosteroneDihydrotestosteroneEstradiolEstroneFemaleFertilityFollicle Stimulating HormoneHumans20-alpha-DihydroprogesteroneAndrogensAnti-Mullerian HormoneCOVID-19 VaccinesDehydroepiandrosteroneDihydrotestosteroneEstradiolEstroneFollicle Stimulating HormoneAMHantral follicle countCOVID-19infectionsafetysteroidsvaccinationwoman fertility

Identifiers

PMID36142820
PMCPMC9501189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.